Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2026-02-12 Interim / Quarterly Rep…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Zelluna ASA: Fjerde kvartal 2025 - Viktig regulatorisk milepæl oppnådd med CTA-innlevering - Attachment: Zelluna-ASA-Q425-Report.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Fourth Quarter Report' for Zelluna ASA for the period ending December 31, 2025. It contains comprehensive financial highlights, a table of key financials (Q4-25, Q4-24, FY25, FY24), an operational review, and a CEO statement. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q4 2025
2026-02-12 English
Zelluna ASA: Fourth Quarter 2025 - Key regulatory milestone achieved with CTA Submission - Attachment: Zelluna-ASA-Q425-Presentation.pdf
Investor Presentation Classification · 100% confidence The document is a 'Fourth Quarter 2025 Business Update and Financial Results' presentation for Zelluna ASA. It contains detailed slides on business progress, clinical trial updates, pipeline status, and financial performance (P&L, cash position). It is clearly intended for investors to provide a comprehensive overview of the company's strategy and financial health, fitting the definition of an Investor Presentation.
2026-02-12 English
Zelluna ASA: Fjerde kvartal 2025 - Viktig regulatorisk milepæl oppnådd med CTA-innlevering
Earnings Release Classification · 100% confidence The document is a short announcement (4066 characters) from Zelluna ASA regarding their Q4 2025 financial results. It provides key highlights, financial metrics, and operational updates, and explicitly mentions that the full quarterly report and presentation will be made available on their website. Following the 'Menu vs Meal' rule, this document serves as an initial announcement of the results rather than the full report itself, making it an Earnings Release (ER). Q4 2025
2026-02-12 Norwegian
Zelluna ASA: Fourth Quarter 2025 - Key regulatory milestone achieved with CTA Submission
Earnings Release Classification · 95% confidence The document is an announcement of quarterly financial results (Q4 2025) for Zelluna ASA. It provides key operational and financial highlights, such as operating expenses, losses, and cash position, and mentions that the full quarterly report and presentation will be made available on the company website. Given the document length (4082 characters) and its function as a summary announcement of results rather than the full report itself, it is classified as an Earnings Release. Q4 2025
2026-02-12 English
Zelluna ASA - Grant of Share Options
Share Issue/Capital Change Classification · 95% confidence The document announces the grant of share options to employees, including primary insiders (CFO and CTO). While it involves directors/insiders, it is specifically an announcement of a share-based incentive grant rather than a report of a personal transaction in existing shares. Under the provided definitions, this fits best as a regulatory announcement regarding capital/share-related incentives, and since it does not fit into the specific 'Director's Dealing' (which usually implies trading of existing shares) or 'Share Issue' (which implies a change in capital structure), it is classified as a Regulatory Filing (RNS) as the fallback category for corporate announcements of this nature.
2026-02-05 English
Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation
Report Publication Announcement Classification · 100% confidence The document is an invitation to a webcast presentation for upcoming financial results. It is short (1454 characters), does not contain the actual financial results, and explicitly states that the quarterly report and presentation materials will be published on a future date. This fits the definition of a Report Publication Announcement (RPA) as it serves to notify stakeholders of the timing and availability of upcoming reports.
2026-02-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.